Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Patients With Rheumatoid Arthritis Who Had Poor Response To Other Drugs Could Have Better Results With Golimumab
An article published Online First and in this week"s edition of reports information about Golimumab, a new tumour necrosis factor-í± (TNF-í±) inhibitor. It reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-í± inhibitor. This drug might be a good alternative for patients who have inadequate responses to one or two other TNF-í± inhibitors.
generic viagra online
ReachMD Launches CME iPhone APP
ReachMD, which provides medical news and information to healthcare practitioners, is raising its profile with the Continuing Medical Education, or CME, application for the Apple iPhone and iPod touch. This is the first CME application that lets users listen to all ReachMD Continuing Medical Education content, get regular updates on new Continuing Medical Education content and take Continuing Medical Education tests for credit, all from their iPhone or iPod touch.
News of the day
Prevalence Of Variant CJD Agent In Britain Remains Uncertain
First results from a large tissue survey in Britain of the agent that causes variant Creutzfeldt-Jakob disease (vCJD) are unable so far to establish that the prevalence is lower than that given by previous estimates, concludes a study published on bmj.com today.
Cardiovascular

Maternal Immunity Not All Good For A Fetus

As a fetus does not mount an immune response to maternal proteins that cross the placenta, it has been assumed that a fetus would not reject non-genetically matched blood cells (specifically allogeneic blood cells) if they were transplanted while the fetus was in utero. The hope is that this procedure, which is known as IUHCT, could provide a viable approach for treating congenital blood disorders. However, studies using a mouse model of IUHCT indicate that most fetal recipients of allogeneic blood cells lose their transplanted cells 3-5 weeks after transplantation. Alan Flake and colleagues, at Children"s Hospital of Philadelphia, have now identified an immune mechanism responsible for graft failure in this model of IUHCT. Surprisingly, although fetal immune cells eliminated the transplanted allogeneic blood cells, they were triggered to do so by immune molecules known as alloantibodies that they obtained from their mother"s breast milk. The maternal alloantibodies were produced in response to IUHCT and so the authors conclude that in the absence of either a maternal immune response or transmission of the maternal alloantibodies to the fetus, transplanted blood cells should not be rejected, leaving open the door for IUHCT as a potential clinical strategy. TITLE: Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice AUTHOR: Alan W. Flake Children"s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. PDF of this article. Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009